Incivek Sales Continue To Crater, CF Program Takes The Stage At Vertex
This article was originally published in The Pink Sheet Daily
Vertex’s longer-term strategy in hepatitis C centers on combination trials of Phase II nucleoside VX-135 with three other companies’ candidates. In cystic fibrosis, Kalydeco sales continue to grow as the firm advances other candidates for combination therapy.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.